Editas Medicine Gains Australian Approval for Hyperlipidemia Gene Therapy Trial

Editas Medicine has secured Australian regulatory approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401, a gene therapy designed to treat heterozygous familial hypercholesterolemia. This inherited genetic disorder leads to elevated LDL-C levels. The company anticipates beginning patient dosing in 2026, with initial safety and tolerability data expected in the first quarter of 2027, representing a key advancement in its therapeutic development.